The information on this website is intended for healthcare professionals and provided solely for the purpose of scientific exchange. The available publications and congress materials may contain information that is not included in, or may differ from, product labelling, or may contain information about investigational compounds or uses not yet approved. Availability of this information is not intended to recommend any administration, indication, dosage or other use inconsistent with the approved Prescribing Information. Please refer to the applicable local Prescribing Information for approved uses and product information.
If you do not have personal or institutional subscriptions for a particular article, please submit a Medical Information request. Transfer of value reporting may apply for reprint requests.
Clinical
Nat Med. 2023;29(11):2919-2928. doi:10.1038/s41591-023-02603-1
Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial
Stephen A Harrison, Rebecca Taub, Guy W Neff, K Jean Lucas, Dominic Labriola, Sam E Moussa, Naim Alkhouri, Mustafa R Bashir
October 16, 2023
Clinical
N Engl J Med. 2024;390(6):497-509. doi:10.1056/NEJMoa2309000
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Stephen A Harrison, Pierre Bedossa, Cynthia D Guy, Jörn M Schattenberg, Rohit Loomba, Rebecca Taub, Dominic Labriola, Sam E Moussa, Guy W Neff, Mary E Rinella, Quentin M Anstee, Manal F Abdelmalek, Zobair Younossi, Seth J Baum, Sven Francque, Michael R Charlton, Philip N Newsome, Nicolas Lanthier, Ingolf Schiefke, Alessandra Mangia, Juan M Pericàs, Rashmee Patil, Arun J Sanyal, Mazen Noureddin, Meena B Bansal, Naim Alkhouri, Laurent Castera, Madhavi Rudraraju, Vlad Ratziu 1; MAESTRO-NASH Investigators
February 7, 2024
Clinical
Aliment Pharmacol Ther. 2024;59(1):51-63. doi:10.1111/apt.17734
Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis
Stephen A Harrison, Vlad Ratziu, Quentin M Anstee, Mazen Noureddin, Arun J Sanyal, Jörn M Schattenberg, Pierre Bedossa, Mustafa R Bashir, David Schneider, Rebecca Taub, Meena Bansal, Kris V Kowdley, Zobair M Younossi, Rohit Loomba
October 2, 2023
